Stockwinners Market Radar for September 18, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

21:39 EDT Flex CFO sells $1.38M in common stock - In a regulatory filing, Flex disclosed that its CFO Paul Lundstrom sold 53.5K shares of common stock on September 18th in a total transaction size of $1.38M.

19:38 EDT Semtech director buys $496.5K in common stock - In a regulatory filing, Semtech disclosed that its director Paul Walsh bought 20K shares of common stock on September 18th in a total transaction size of $496.5K.

18:46 EDT Oracle CEO: We continue to accelerate in our growth - In an interview on CNBC's Mad Money, Safra Catz said Oracle has so much demand, it keeps booking it. In the first week this quarter, it booked $1.5B in just AI workloads. "We spent a lot last year in setting up the base for our cloud," she noted. She said moving the Cerner business to the cloud is resulting in near term headwinds for that unit. "Cerner is an opening to bring healthcare to the 21st century," she added.

18:13 EDT Enviri to name Tom Vadaketh as CFO, effective October 16 - Enviri (NVRI) announced Tom Vadaketh will be appointed as Senior Vice President and CFO, effective October 16. Vadaketh will succeed Pete Minan, who previously announced plans to retire and has been serving as Interim CFO. Vadaketh joins Enviri with more than 30 years of financial experience, most recently serving as CFO of Bausch Health (BHC), a $4.5B pharmaceutical and medical aesthetics company.

17:23 EDT Stitch Fix sees Q1, FY24 gross margin 43%-44% - Says expects inventory balances to rise in Q1. Says focused in delivering long-term profitable growth. Says this is pivotal time for the company. Says unlocked leverage potential for the business. Says Q4 performance was better than expected. Says expects full closure of UK operations to be completed by end of calendar year. Says anticipates reporting UK results as discontinued operations in Q1. Says FY24 guidance assumes the company is free cash flow positive for the year. Sees Q1 UK revenue $7M. Comments and guidance taken from Q4 earnings conference call.

17:07 EDT Farmer Bros. director buys $206.2K in common stock - In a regulatory filing, Farmer Bro disclosed that its director Bradley Radoff bought 80K shares of common stock on September 15th in a total transaction size of $206.2K.

17:05 EDT NY financial regulator gives further guidance for Greenlisted coins - Adrienne A. Harris, Superintendent of Financial Services said in a release: "Unless otherwise informed by the New York State Department of Financial Services or DFS , virtual currency business entities that are either licensed under 23 NYCRR Part 200 or chartered as a limited purpose trust company under the New York Banking Law , do not need the Department's prior approval to list coins included on the Greenlist. VC Entities that choose to list Greenlisted coins must, however: 1) provide advance notification to DFS prior to beginning support; and 2) have a DFS-approved coin-delisting policy. The Greenlist is wholly separate and independent from any individual VC Entities' coin-listing policies and resulting self-certifications. In general, DFS will consider adding a coin to the Greenlist if: 1) the coin or coin issuer has a demonstrated, historic record consistent with safety and soundness and the protection of customers, including broad marketplace adoption, or 2) the coin is a stablecoin approved by DFS for issuance in New York by a VC Entity.1 DFS may, at any time and in its sole discretion, add any coin to the Greenlist; remove any coin from the Greenlist; refrain from placing any coin on the Greenlist; discontinue the Greenlist process entirely; prohibit or otherwise limit a coin's use before or after a VC Entity begins using a coin; or require that any VC Entity delist, halt, or otherwise limit or curtail activity with respect to any coin. U.S. Dollar-backed stablecoins approved for issuance in New York are subject to the Department's Guidance on the Issuance of U.S. Dollar-Backed Stablecoins." Publicly traded companies in the space include Bit Digital (BTBT), Coinbase (COIN), Core Scientific (CORZ), Greenidge Generation (GREE), Marathon Digital (MARA), MicroStrategy (MSTR), Riot Platforms (RIOT), Stronghold Digital Mining (SDIG), TeraWulf (WULF), Bitcoin Investment Trust (GBTC). Reference Link

16:43 EDT Booking Holdings CFO sells $1.76M in common stock - In a regulatory filing, Booking Holdings disclosed that its CFO David Goulden sold 550 shares of common stock on September 15th in a total transaction size of $1.76M.

16:42 EDT Air Lease announces lease placements of one Airbus A330-200 with HiSky - Air Lease announced a long-term lease placement for one Airbus A330-200 aircraft with HiSky. Scheduled to deliver to the European carrier in 2023, this A330-200 aircraft joins one A319-100, four A320-200s and two A321-200neo LR aircraft currently on lease to HiSky from ALC.

16:36 EDT Norfolk Southern announces Value Assurance Program for East Palestine homeowners - Norfolk Southern announced Monday an interim Value Assurance Program. The VAP will compensate any reduction in value of eligible residential properties located in East Palestine, Ohio and some surrounding communities following the February derailment. This announcement comes as Norfolk Southern is working toward a long-term program as part of broader commitments the company made in March 2023. "This is another step in fulfilling our promise to East Palestine to make it right. Norfolk Southern is steadfast in keeping our commitments, including protecting the home values of the community," said Alan H. Shaw, President and CEO of Norfolk Southern. "This program aims to give homeowners the reassurance they need." Through the interim VAP, those residents in the defined program area who have sold their homes since February 3, currently have their homes on the market, or will put their homes on the market, are eligible to be compensated for any difference between their home's market value and its sale price. The interim VAP will also be available for future sales as Norfolk Southern develops the full long-term program in concert with stakeholders involved in that legal process. At the time of the long-term VAP announcement, the interim plan will end, and the long-term VAP requirements will apply. The interim VAP, and any monetary benefits received by those participating in the interim VAP, is available to eligible property owners. Eligible property owners will work with independent appraisers to assess the value of their home, and with the Norfolk Southern Family Assistance Center after the sale to recoup any difference.

16:31 EDT SuperCom receives Nasdaq letter on minimum bid requirements - SuperCom received a letter from Nasdaq, indicating that the company was not in compliance with Nasdaq Listing Rule 5550(a)(2), as the company's closing bid price for its common stock was below $1.00 per share for the 30 consecutive business days prior to the Notice, between August 1, 2023 and September 11, 2023. SuperCom expects to regain compliance with the minimum bid price requirement within the upcoming 180 days compliance period.

16:29 EDT Microvast director Zheng sells 313,009 common shares - In a regulatory filing, Microvast Holdings director Yanzhuan Zheng disclosed the sale of 313,009 common shares of the company on September 15 at a price of $2.02 per share.

16:27 EDT NYSE to commence delisting proceedings against Lightning eMotors - The New York Stock Exchange announced that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock and redeemable warrants of Lightning eMotors from the NYSE. Trading in the company's securities will be suspended immediately. "NYSE Regulation reached its decision to delist the company's securities pursuant to Section 802.01B of the NYSE's Listed Company Manual because the company had fallen below the NYSE's continued listing standard requiring listed companies to maintain an average global market capitalization over a consecutive 30 trading day period of at least $15,000,000. The company has a right to a review of this determination by a Committee of the Board of Directors of the Exchange. The NYSE will apply to the Securities and Exchange Commission to delist the securities upon completion of all applicable procedures, including any appeal by the company of the NYSE Regulation staff's decision," the exchange stated. Reference Link

16:26 EDT Global Ship Lease teams with Bayes Business School on UK-MaRes Hub - Global Ship Lease announced its project partnership supporting Bayes Business School in leading the Digitization, Maritime Operations, and Finance aspects of the consortium's successful bid for the UK National Clean Maritime Research Hub . Alongside other project partners from across the energy and supply chain sectors, GSL will provide support for work to accelerate decarbonization, reduce emissions, and drive economic and societal benefits in the transition to a clean maritime future. Among a range of issues related to maritime decarbonization, the UK-MaRes Hub will pursue initiatives related to the scalability and safety of emerging marine fuels; alternative power and propulsion systems; port and vessel support systems; vessel design and efficiency; maritime operations and digitization; and economics, finance, and policy.Thomas Lister, Chief Commercial Officer and Head of ESG at Global Ship Lease, commented, "We are proud to participate in this pioneering research effort that brings together a range of experts from across government, academia, and industry in pursuit of solutions to the key technological, economic, and societal challenges of decarbonization. By bringing our real world technical and operating expertise, experience, and data to this effort in conjunction with Bayes Business School and the diverse group of project partners, we hope to add to growing momentum in the drive towards net zero emissions in shipping, and to ensure that GSL stays ahead of the curve on issues that are increasingly central to both our industry and the world at large."

16:22 EDT Cepton to consolidate shares with 1-for-10 reverse stock split - Cepton announced has approved a 1-for-10 reverse stock split of its common stock, par value $0.00001 per share that is expected to become effective on Thursday, September 21, 2023 at 5:00 p.m. Eastern Time. The company's Common Stock is expected to begin trading on a split-adjusted basis on the Nasdaq Stock Market at the open of trading on September 22, 2023 under the existing symbol "CPTN" and new CUSIP number 15673X200. At Cepton's special meeting of stockholders on September 7, 2023, stockholders approved the proposal to authorize the Board to effect a reverse split at a ratio ranging from 1-for-5 to 1-for-20.

16:21 EDT U.S. Steel up about 2% at $31.02 after above-consensus Q3 pre-announcement

16:18 EDT Histogen to resume trading at 4:35 pm ET - Histogen is scheduled to resume trading at 4:35 pm ET, with quotation set to resume at 4:30 pm ET, according to Nasdaq. Shares were halted, pending news, ahead of Histogen having announced that its board, after "extensive consideration of potential strategic alternatives," has approved and adopted a plan of dissolution that would include the distribution of remaining cash to stockholders following an orderly wind down of the company's operations, including any proceeds from the potential sale of any pipeline assets.

16:16 EDT Histogen Board adopts Plan of Dissolution, including distribution of cash - Histogen announced that its Board of Directors, after extensive consideration of potential strategic alternatives, has approved and adopted a Plan of Dissolution that would include the distribution of remaining cash to stockholders following an orderly wind down of the company's operations, including any proceeds from the potential sale of any pipeline assets. In order to reduce costs and in connection with the Plan of Dissolution, the company has discontinued all clinical development programs and reduced its workforce, including the anticipated termination of most employees by the end of September. "The Board of Directors and management devoted substantial time and effort in identifying and pursuing various opportunities, but we were unable to complete a transaction that would allow us the potential to enhance stockholder value," stated Steven J. Mento, Ph.D., President and Chief Executive Officer of Histogen.

16:15 EDT Hawaiian Electric CFO Sekimura to retire September 30 - Hawaiian Electric Industries announced the following leadership plans at HEI and Hawaiian Electric Company, a subsidiary of HEI, effective October 1, 2023: Hawaiian Electric SVP, CFO & Treasurer Tayne Sekimura will retire on September 30, 2023, after 32 years of service. Sekimura's retirement plans were announced internally early this year. Hawaiian Electric is at an unprecedented point in its history in the wake of the August 8 tragedy on Maui. Hawaiian Electric had been progressing on naming a successor to Sekimura but these plans were upended by the August events. Consequently, Paul Ito, currently EVP, CFO & treasurer of HEI, will serve as SVP, CFO & treasurer of Hawaiian Electric until approximately December 31, 2024 to assist the utility during this critical period, ensure a seamless transition and provide additional time for the utility to appoint a successor to Sekimura. Ito will return to HEI and resume his original role immediately following his term at Hawaiian Electric. Scott DeGhetto has been appointed EVP, CFO & treasurer of HEI, effective October 1, 2023 through approximately December 31, 2024. DeGhetto joins HEI from Moelis & Company, bringing over 30 years of experience and significant expertise in the power, utility and renewable energy sectors. DeGhetto will remain at HEI in an advisory role from approximately January 1, 2025 until April 1, 2025 to provide for a transition around Ito's return.

16:13 EDT Beyond Air: New data supports development of nNOS inhibitors for ASD treatment - Beyond Air announced the publication of new data that support ongoing preclinical development of selective nNOS inhibitors for the treatment of Autism Spectrum Disorder, ASD. The Hebrew University of Jerusalem or HUJI, has previously published studies suggesting that NO is a pathologic factor in ASD. In previously published studies, 10-day daily injections of 7-nitroindazole, 7-NI,, a selective nNOS inhibitor, reversed the manifestations of ASD phenotype, and reversed nitrosative stress. These new data published by HUJI, available online at ScienceDirect provide additional evidence for the efficacy of selective nNOS inhibitors in the treatment of ASD. The novel extended-release gel formulation maintained the plasma level of 7-NI at ~45 microgram/ml/day for approximately 10 days. The researchers observed improved cognitive memory, social interaction and reduced anxiety-like behavior in Shank mutant mice. This was accompanied by a reduction in 3-nitrotyrosine levels . Steve Lisi, Chairman and Chief Executive Officer of Beyond Air, stated, "These new data from HUJI reinforce previously published efficacy data, and provide strong evidence to suggest a convenient dosing regimen for patients. We are pleased to have such a dedicated partner in HUJI and look forward to advancing this program as quickly as possible." The collaboration between Beyond Air and HUJI to develop selective nNOS inhibitors for the treatment of ASD is being conducted under a research and license agreement signed via Yissum, Research Development Company of the Hebrew University. "These novel data provide new evidence of the role of nitric oxide in autism. It further proves the efficacy of the nNOS inhibitors for ASD treatment. The novel sustained release strategy will open the door for the feasibility of such a treatment," stated Prof. Haitham Amal, B.Sc.Pharm, Ph.D., Assistant Professor at the School of Pharmacy, Faculty of Medicine at the Hebrew University. "We are eager to reach our ultimate goal of developing therapeutics for ASD."

16:11 EDT Sonos CEO Patrick Spence joins Snap board of directors - Snap (SNAP) announced that Patrick Spence, Chief Executive Officer and member of the board of directors of Sonos, Inc. (SONO), has been appointed to the company's board of directors, effective as of September 14, 2023.

16:09 EDT Block says Square CEO Henry to depart, effective October 2 - In a regulatory filing, Block reported that Alyssa Henry, the Square Chief Executive Officer of Block, will depart the company effective October 2. "Ms. Henry has worked at Block for over nine years and provided significant contributions to the company during that time," the company stated. Jack Dorsey, the company's Block Head and Chairperson, will also serve as the Square Head, the filing noted.

16:06 EDT Lightning eMotors trading halted, news pending

16:06 EDT Indie Semiconductor acquires Exalos AG for $45M - indie Semiconductor announced it has entered into a definitive agreement and completed the acquisition of privately held EXALOS AG, a Swiss photonics company, specializing in the design of high-performance optical semiconductors. Subject to the terms and conditions of the definitive agreement, indie paid approximately $45 million to EXALOS equity holders comprised of 6.6 million indie Class A common shares. In addition, if certain revenue-based performance targets are exceeded over a 24-month post-closing period, there is an opportunity for such holders to earn up to $20 million more in cash or indie Class A common shares, at indie's election. The transaction has been approved by the boards of directors of both indie and EXALOS. The acquisition is expected to be financially neutral in 2023 and accretive to indie's 2024 results.

16:05 EDT Kinnate Biopharma trading halted, news pending

16:01 EDT Histogen trading halted, news pending

14:50 EDT CF Acquisition Corp VIII trading resumes

14:31 EDT Digital Transformation Opportunites Corp trading resumes

13:38 EDT California AG announces lawsuit against oil, gas companies - Joined by California Governor Newsom, California Attorney General Rob Bonta announced over the weekend the filing of a lawsuit against five of the largest oil and gas companies in the world - Exxon Mobil (XOM), Shell (SHEL), Chevron (CVX), ConocoPhillips (COP), and BP (BP) - and the American Petroleum Institute for allegedly engaging in a decades-long campaign of deception and creating statewide climate change-related harms in California. Filed in San Francisco County Superior Court, the complaint asserts that "although the companies have known since at least the 1960s that the burning of fossil fuels would warm the planet and change our climate, they denied or downplayed climate change in public statements and marketing." As detailed in the complaint, "California has spent tens of billions of dollars to adapt to climate change and address the damages climate change has caused so far, and the state will need to spend multiples of that in the years to come." Attorney General Bonta, "on behalf of the people of California, is seeking nuisance abatement through the creation of a fund to finance climate mitigation and adaptation efforts; injunctive relief to both protect California's natural resources from pollution, impairment, and destruction as well as to prevent the companies from making any further false or misleading statements about the contribution of fossil fuel combustion to climate change; damages; and penalties." Reference Link

13:02 EDT Old Republic announces formation of new accident & health company - Old Republic International Corporation announced that it is forming a new underwriting subsidiary to provide Accident & Health insurance products. The new company, Old Republic Accident & Health, Inc., will focus on providing specialized coverages such as employers stop loss and will be led by Gary Nidds as President, the company said in a statement. Craig R. Smiddy, ORI's President and CEO, noted that, "Old Republic Accident & Health will expand our risk expertise and appetite into a new segment that aligns with our specialized approach and focus on underwriting excellence."

12:00 EDT Miniso falls -7.0% - Miniso is down -7.0%, or -$1.98 to $26.17.

12:00 EDT Unity falls -7.9% - Unity is down -7.9%, or -$2.88 to $33.44.

12:00 EDT Knowles rises 7.3% - Knowles is up 7.3%, or $1.04 to $15.29.

11:32 EDT GDIT says 'swept' initial task orders on $4.5B Air Force Security Support pact - General Dynamics Information Technology, or GDIT, a business unit of General Dynamics, announced that it "swept all initial task orders" on the $4.5B Department of the Air Force Security Support Services indefinite-delivery/indefinite quantity contract. "The value of these task orders cannot be disclosed due to program sensitivities. The multiple-award, indefinite-delivery-indefinite quantity contract, initially awarded in February 2021, includes a five-year base period and a five-year option. Following multiple protests by a competitor, the Air Force notified GDIT in August 2023 that all protests were resolved. Under the contract, which is expected to start on Nov. 15, GDIT will implement comprehensive security services including information, personnel and communications security as well as counterintelligence analysis and cybersecurity assessments," the company stated.

11:13 EDT Ivanhoe Mines reports fatality at Kamoa-Kakula copper complex - Ivanhoe Mines regrets to report that a fatal accident has occurred at the Kamoa-Kakula Copper Complex in the Democratic Republic of Congo. "A fatal accident occurred underground at the Kakula mine when Mr. Mick Ilunga, a contractor drill rig operator, was struck by a fall of ground. A second contractor drill rig operator is receiving medical treatment for non-life-threatening injuries. Kamoa Copper is undertaking a comprehensive internal investigation into the accident and is working with the DRC authorities to facilitate their investigation of the accident. Once the investigations are complete, management will review and implement any additional safety measures recommended to prevent such an accident from recurring. On behalf of the Kamoa Copper Joint Venture, Ivanhoe Mines extends its deepest condolences to the grieving family and friends of Mr. Ilunga. Mining activities at the Kakula underground mine have temporarily ceased. The Phase 1 and 2 concentrators continue to operate, drawing from surface ore stockpiles," the company stated.

10:32 EDT T. Rowe Price names Ramon Richards as Chief Technology Officer - T. Rowe Price announced Ramon Richards as its new Chief Technology Officer. Ramon joined the firm on September 5, and as CTO, he leads technology business solutions, technology services, and enterprise architecture functions. Richards most recently served as chief information officer at Fannie Mae, the company noted. "Ramon Richards is a seasoned technology executive who is recognized for transformation, modernization, and leading a complex technology organization. He is the ideal leader to guide our technology teams and strategy to enhance our ability to deliver reliable, user-friendly solutions that drive business results," said Kimberly Johnson, Chief Operating Officer at T. Rowe Price.

10:28 EDT Panos Panay confirms leaving Microsoft - Panos Panay, EVP and Chief Product Officer at Microsoft, tweeted: "After 19 incredible years at Microsoft, I've decided to turn the page and write the next chapter. I'm forever grateful for my time at Microsoft and the amazing people I had the honor to make products with." Reference Link

10:17 EDT XOMA trading resumes

10:12 EDT CVD Equipment trading resumes

10:08 EDT Correction: Skye Bioscience did not sign MOU with Prime Minister of Serbia - A headline that previously stated on September 8 that Skye Bioscience had signed an MOU with the Prime Minister of the Republic of Serbia was issued in error. SK bioscience had announced that Ana Brnabi, Prime Minister of the Republic of Serbia has visited the SK bioscience headquarters and signed a memorandum of understanding with the company to establish a strategic partnership in vaccine development and manufacturing.

10:00 EDT L.S. Starrett Co falls -7.4% - L.S. Starrett Co is down -7.4%, or -84c to $10.50.

10:00 EDT Unity falls -9.0% - Unity is down -9.0%, or -$3.26 to $33.06.

10:00 EDT ZIM Integrated rises 5.6% - ZIM Integrated is up 5.6%, or 62c to $11.62.

10:00 EDT Hyliion Holdings, Cummins obtain Dual Executive Order from CARB - Hyliion Holdings (HYLN) and Cummins Inc. (CMI) announced the two companies together have successfully obtained the Dual Executive Order from the California Air Resources Board, or CARB, for the Hypertruck ERX powertrain paired with the Cummins ISX12N engine.

09:54 EDT SeqLL Inc trading resumes

09:47 EDT Neptune Wellness intends to spinout Sprout Organics - Neptune Wellness Solutions (NEPT) announced that after careful consideration and evaluation of potential strategic alternatives to enhance the Company's value, the Board of Directors has approved a plan to proceed with a spinout to Neptune shareholders of a majority of its equity interest in Sprout Organics, an organic baby food and toddler brand. Upon completion of the spinout, which would follow the previously announced exchange by Neptune of existing Sprout debt for Sprout equity, pursuant to the term sheet entered into with Morgan Stanley (MS) as previously announced on August 17, 2023, it is anticipated that Neptune would spinout a majority of its equity interest in Sprout to current Neptune shareholders, and Neptune would keep a retained interest of approximately 10-15%. The Company believes there are many benefits in proceeding with the contemplated spinout transaction, including reducing Neptune's operating costs and cash requirements and generally reducing Neptune's debt exposure, such that Neptune's overall financial position and cash flows would be improved. Neptune will provide updates when further details of the proposed spinout transaction are determined. Neptune continues to evaluate additional available strategic options for the Company to unlock and maximize shareholder value, including strategic business and financial alternatives, which may include, but is not limited to, the monetization of assets, strategic partnerships, etc. The completion of the proposed spinout transaction and contemplated distribution of Sprout shares to Neptune shareholders are subject to a number of conditions, including the completion of legal and tax structuring analyses, completion of financial analysis, determination of the structure of Sprout, determination of final details of the transaction, settlement of the board and management team for Sprout, required regulatory approvals, any required shareholder approval, Neptune's compliance with its debt agreements, and the listing of the Sprout shares on a stock exchange. There is no certainty that the foregoing conditions will be satisfied or that the spinout transaction will be completed on the terms proposed or at all. The Board of Neptune may determine to not proceed with the transaction should there be a change in market conditions or investor interest or should another opportunity arise that would be deemed to better enhance value to Neptune stakeholders.

09:47 EDT Offerpad Solutions falls -6.1% - Offerpad Solutions is down -6.1%, or -63c to $9.77.

09:47 EDT Emergent BioSolutions rises 4.5% - Emergent BioSolutions is up 4.5%, or 18c to $4.15.

09:47 EDT GreenTree Hospitality rises 5.5% - GreenTree Hospitality is up 5.5%, or 23c to $4.45.

09:44 EDT Neptune Technologies trading halted, volatility trading pause

09:40 EDT Paratek announces stockholder approval of acquisition by Gurnet, Novo - Paratek Pharmaceuticals announced, based on a preliminary vote count, that stockholders have approved the merger agreement proposal at Paratek's special meeting of stockholders, in connection with the previously announced definitive agreement to be acquired by Gurnet Point Capital and Novo Holdings A/S. Final voting results for the special meeting will be disclosed on Form 8-K filed by Paratek with the U.S. Securities and Exchange Commission.

09:38 EDT Knowles to acquire Cornell Dubilier for $263M - Knowles "announced strategic actions to accelerate its transformation to an industrial technology company focused on higher growth and higher value opportunities. The Company has entered into a definitive agreement to acquire Cornell Dubilier in an all-cash transaction. In parallel, Knowles announced that it is evaluating strategic alternatives for its Consumer MEMS Microphones business. Cornell Dubilier, based in Liberty, South Carolina, is a technology leader and manufacturer of high-quality film, electrolytic and mica capacitors used in demanding medtech, military, aerospace, and industrial electrification applications with an annualized revenue of more than $135 million and over 35 thousand customers. The total cost of the acquisition is $263 million and consists of a $140 million cash payment at closing and an interest-free seller note of $123 million, with $50 million maturing one year from closing and the remaining $73 million maturing two years from closing. The total fair value of the consideration transferred is estimated at $250 million and represents 9.6x Cornell Dubilier's trailing-twelve-month adjusted EBITDA inclusive of run-rate cost synergies. Knowles expects to finance the acquisition with a combination of cash on hand, borrowings from its existing revolving credit facility, and the seller note. The acquisition is expected to close in the fourth quarter of calendar year 2023, subject to regulatory approvals and other customary closing conditions."

09:37 EDT Volcon implements cost reduction strategies ahead of Stag introduction - Volcon announced on September 14, 2023 that it has agreed with its convertible noteholders to modify the terms of its convertible notes and implemented cost reduction strategies to provide the Company greater flexibility as it pushes toward the introduction of the first of its UTV models, the Stag, which the Company expects to begin delivering in October 2023. The Company entered into a note amendment with its convertible noteholders pursuant to which the lenders agreed to, among other changes, extend the maturity of the outstanding convertible notes from February 24, 2024 to January 31, 2025 and modify certain covenants to allow the Company to execute its business strategy as it works toward the launch of the Stag. The amendment is subject to completion of a security agreement establishing a security interest in the assets of the Company for the benefit of the noteholders. The Company recently implemented further cost reduction initiatives and is continuing to evaluate its cost structure to identify incremental savings. In addition, the Company has reduced cash expenses by agreeing to eliminate cash bonuses payable to the Company's officers in favor of stock awards and the Chief Executive Officer, Chief Financial Officer and Chief Operating Officer have voluntarily agreed to reduce their salaries by 10%. The Company's board of directors has also agreed that all future quarterly board cash fees will be payable in the form of stock awards as well. On September 13, 2023, the Company announced additional trim packages and pricing for the Stag. The initial response by existing reservation holders who made deposits and viewed new trim level selections has been positive. The Company continues to follow up with all pre-order reservation holders to make sure they are aware of the trim package options and answer any questions they may have. The Company also realized new customer preorders which further supports the Stag product line and the future of EV in powersports. The Company has two consumer lending firms providing financing to consumers, Synchrony Bank and Octane Roadrunner Financial, which can be found on Volcon.com or by contacting Volcon dealers for more information. In addition, the Company's sales team is connecting with dealers and distributors to place pre-orders. The overwhelming majority of dealers are committed to selling Volcon products and are excited that the Stag is finally coming to market. The Company is also working with a finance company to obtain a facility that will allow the Company to place Stags with dealers for small cash outlays allowing the Company to generate cash to reinvest in additional dealer placements. This facility will allow dealers to finance their Stag purchases.

09:32 EDT Crown Electrokinetics executes master services agreement with new customer - Crown Electrokinetics announced it has executed a Mater Services Agreement with one of the largest contractors in the United States. Crown's new customer has significant operations in Arizona as well as 19 other states. Crown expects to commence the first two projects in Arizona in October through the deployment of traditional drilling, along with its newly acquired micro trenching equipment. Total revenue potential of the first two projects is expected to be up to $70 million.

09:29 EDT Steel Dynamics down 3% at $95.70 after negative Q3 pre-announcement

09:19 EDT DoorDash expands partnership with ALDI to offer 'responsible' alcohol delivery - DoorDash expanded their partnership, announcing that consumers can now order on-demand alcohol delivery from more than 1,200 ALDI locations across 21 states on DoorDash. With the addition of ALDI, one of America's fastest-growing retailers, nearly 80% of DoorDash consumers can now access alcohol through safe, age-verified delivery. DoorDash Expands Partnership with ALDI to Offer Responsible Alcohol Delivery (Photo: Business Wire)"In addition to giving merchants a new way to reach customers, on-demand alcohol delivery helps partners grow their business. On DoorDash, adding alcohol may increase grocers' average order value by up to 30%. Order values for U.S. convenience orders were on average over 50% higher when alcohol was added," said Fuad Hannon, Vice President of New Verticals at DoorDash. "We've worked hard to build a trusted alcohol ordering and delivery experience. The expansion of our partnership with ALDI reinforces our commitment to provide growth opportunities for local merchants, while simultaneously providing a safe, high-quality experience for customers."

09:17 EDT DoorDash broadens grocery selection with multiple new partners - DoorDash announced multiple new grocery partners, continuing its swift acceleration in the category. From the largest national grocery partners to beloved local favorites and specialty shops, DoorDash creates more opportunities for retailers of all sizes to reach consumers online. "We've made significant progress in investing in long-term partnerships with grocers of all sizes, all while remaining focused on improving quality and execution. The grocers announced today recognize DoorDash as a source of incremental growth, accelerating what we believe to be the fastest-growing platform for grocery in North America," said Fuad Hannon, Vice President of New Verticals at DoorDash. "We strive to be the rising tide that lifts all boats - driving growth for retailers while helping consumers stock up on groceries whenever and however is best for them." Today, DoorDash is excited to announce new grocery partners available on the DoorDash Marketplace, including CUB, Eataly, El Super, Fiesta Mart, Lowe's Markets, Pruett's Food, Stater Bros. Markets, and Strack & Van Til. CUB - With the addition of CUB to the DoorDash Marketplace, consumers can get on-demand delivery from 79 grocery locations throughout Minnesota from fresh produce to a full selection of meat and seafood, deli and bakery favorites, pet food, gift cards, flowers and a full pharmacy. Also added to the platform are 31 Cub Wine & Spirits and Cub Liquor locations which offer a wide selection of spirits, wine, beer, seltzers and ready to drink cocktails. Eataly - Founded in 2007, Eataly is the world's largest Italian retail and dining experience. Dedicated to providing the highest quality Italian food across the globe, the company's innovative "eat, shop & learn" model gives guests the opportunity to explore restaurants, cafes, and over 10,000 artisan-made products under one roof. With the ability to now order on-demand grocery delivery from seven Eataly stores, including New York City, Boston, Chicago, Dallas, Los Angeles, and Silicon Valley locations, consumers can create an authentic Italian meal at home. El Super - Customers can now take advantage of on-demand grocery delivery from 65 locations across California, New Mexico, Nevada, Arizona and Texas. El Super combines quality and value with a vast selection of grocery products from Latin America as well as household essentials. Fiesta Mart - In Texas, shoppers can now order from 59 Fiesta Mart store locations in Houston, Dallas and Austin. Known for its variety of international products, Fiesta Mart focuses on offering extensive perishable departments all at the lowest possible prices.

09:10 EDT Lantern Pharma announces FDA clearance of LP-284 IND application - Lantern Pharma announced that the FDA has cleared the investigational new drug, or IND, application for LP-284. LP-284 is being developed for the treatment of relapsed or refractory non-Hodgkin's lymphoma, including mantle cell lymphoma and double hit lymphoma and other high-grade B-cell lymphomas. Lantern expects to commence enrollment of patients for the first-in-human Phase 1 trial for LP-284 during the fourth quarter of 2023.

09:09 EDT Siyata Mobile announces follow-on order from waste management provider - Siyata Mobile has received a follow-on order from an existing customer for additional units of its SD7 handsets and VK7 vehicle kits. A large North American waste management company placed an initial order for the Company's SD7 handsets and VK7 vehicle kits earlier this year. The Company delivered those devices in the third quarter, and subsequently, the waste management company placed a follow-on order for additional units. The Company expects to deliver the follow-on order in the third quarter of 2023.

09:08 EDT Natera promotes John Fesko to chief business officer - Natera announced three appointments within its senior leadership team, effective immediately. John Fesko has been promoted to president and chief business officer, with oversight of reimbursement strategy and market access, patient operations and experience, marketing and communications, government affairs, business and market development, pharmaceutical services, and international commercial operations and strategy. Solomon Moshkevich, president of clinical diagnostics, joined Natera in 2011.

09:06 EDT AvePoint announces anchor investment by 65 Equity Partners - AvePoint announced a definitive agreement has been entered into for an anchor investment by 65 Equity Partners through its purchase of 16,666,600 AvePoint shares of common stock from Sixth Street. "We are pleased to welcome 65 Equity Partners as a substantial long-term stockholder of AvePoint," said Dr. Tianyi Jiang, Co-Founder & CEO, AvePoint. "This investment reflects their confidence in our vision to advance the digital workplace, capture growing markets and prioritize profitable growth. The APAC region represents an enormous growth opportunity for us, and given that Singapore is an important innovation center for AvePoint, we believe that an eventual dual listing on the Singapore Exchange will garner additional investor support in the region."

09:05 EDT EnWave reports acquisition of Eregli Agrosan by Alarko Holdings - EnWave announced that it has approved the acquisition of Ereli Agrosan Doal undefinedrunler ve Turevleri Tarm undefinedretim ve Ticaret A., a Turkish licensor of the Company's Radiant Energy Vacuum dehydration technology, by Alarko Tarim Sanayi ve Ticaret A which is a subsidiary of Alarko Holdings A.S., one of the largest and most respected business conglomerates in Turkey. Alarko Tarm has acquired 100% of Eregli and has been assigned the existing license between EnWave and Eregli. Alarko Tarm intends to make material investments into Eregli to expand its drying business and further improve the commercialization of their REV-dried product portfolio. Eregli currently produces an extensive list of dried fruit, vegetable and dairy products using REV technology.

09:04 EDT Financial Institutions names Jones as SVP, CMO of Five Star Bank - Financial Institutions (FISI) announced that Blake Jones has joined as Senior Vice President, Chief Marketing Officer, CMO, of the Bank. In this role, Jones will support development of the strategic framework and long-term vision for the Bank. She will lead both marketing and analytics on an enterprise-wide basis, focusing on strategy, brand and performance marketing, and audience insights. Jones will report to Justin K. Bigham, Executive Vice President, Chief Community Banking Officer. Jones joins Five Star from Arrow Financial (AROW), where she most recently served as Senior Vice President, Marketing Director.

09:02 EDT Ibex announces $30M share repurchase program - IBEX Limited will commence a stock repurchase program beginning September 18, 2023. The board of directors has authorized a share repurchase plan under which the Company may repurchase up to $30 million of its shares over the next 6 months.

09:02 EDT DIRECTV, Nexstar Media reach new multi-year distribution agreement - DIRECTV and Nexstar Media Group have officially reached a comprehensive new multi-year distribution agreement covering 176 Nexstar-owned local television stations and the company's national cable news network, NewsNation. This follows the return of the television stations and NewsNation to DIRECTV, DIRECTV STREAM and U-verse on the morning of Sept. 17. Terms of the agreements were not disclosed.

09:00 EDT Arm down 4% in pre-market after being started at Underperform at Bernstein - Shares of Arm are down about 4% or $2.31 at $58.44 in pre-market trading after Bernstein initiated the IPO spinoff at Underperform with a $46 price target this morning. The stock was also down 4.5% on Friday.

09:00 EDT Green Plains to acquire its partnership for share percentage plus $2 cash - Green Plains (GPRE) and Green Plains Partners (GPP) announced that they have entered into a definitive merger agreement pursuant to which Green Plains will acquire all of the publicly held common units of the Partnership not already owned by Green Plains and its affiliates in exchange for a combination of Green Plains common stock and cash. Under the merger agreement, each outstanding common unit of the Partnership that Green Plains and its affiliates do not already own will be converted into the right to receive 0.405 shares of Green Plains common stock and $2.00 in cash, plus an amount of cash equal to unpaid distributions from the end of the last quarter for which a quarterly distribution was made to the closing date, as determined in accordance with the merger agreement, without interest. Without taking into account the unpaid distribution amount, the merger consideration represents a value of approximately $15.69 per Partnership common unit as of September 15, , which represents a premium of 20% to the closing price of the Partnership's common units of $13.08 on May 3, 2023, the day immediately prior to Green Plains' initial proposal to acquire all of the publicly held common units of the Partnership not already owned by Green Plains and its affiliates. Green Plains expects that the proposed transaction will simplify its corporate structure and governance, generate near-term earnings and cash flow accretion, reduce SG&A expense related to the Partnership, improve the credit quality of the combined enterprise and align strategic interests between Green Plains shareholders and the Partnership's unitholders by regaining full ownership and control of Green Plains' total platform, including terminal operations.

08:52 EDT Golden Star Acquisition enters merger agreement with Gamehaus - Golden Star Acquisition Corporation entered into a definitive Business Combination Agreement for a business combination. As contemplated by the Merger Agreement, Gamehaus will operate through a publicly-traded holding company listed on the Nasdaq Stock Market. Gamehaus is a technology-driven mobile game publishing company dedicated to nurturing partnerships with and amplifying the success of small- and medium-sized game developers. Gamehaus helps small- and medium-sized game developers stay competitive in the global gaming market with data-driven commercialization support and optimized game distribution solutions. Upon consummation of the Business Combination, Gamehaus Holdings Inc., a newly formed holding company, will seek to be listed on the Nasdaq Stock Market. The outstanding shares of Golden Star and Gamehaus will be converted into the right to receive shares of Pubco. The transaction represents a post-combination enterprise value of $500 million for Gamehaus upon closing of the Business Combination. The transaction has been approved by the boards of directors of both Golden Star and Gamehaus and is expected to be consummated in the fourth quarter of 2023 or early 2024, subject to regulatory approvals, the approvals by the shareholders of Golden Star and Gamehaus, and the satisfaction of certain other customary closing conditions, including that the U.S. Securities and Exchange Commission completes its review of the proxy statement/prospectus relating to the proposed Business Combination, and approval by the Nasdaq Stock Market to list the securities of Pubco. Upon the closing of the Business Combination, the combined company is expected to operate under the name Gamehaus and as a Nasdaq-listed public company trading under a new ticker symbol. Gamehaus' executive management team will continue to lead the combined company. All cash remaining on the combined company's balance sheet at the closing of the transaction, after the settlement of transaction-related expenses, is expected to be utilized by the combined company for working capital, growth, and other general corporate purposes.

08:45 EDT Golden Star Acquisition Corp trading halted, news pending

08:41 EDT Cellectar Biosciences receives EMA PRIME designation for iopofosine - Cellectar Biosciences announced that the European Medicines Agency has granted Priority Medicines designation to iopofosine I 131, the company's lead small-molecule drug candidate, for Waldenstrom's macroglobulinemia in patients who have received two or more prior treatment regimens.

08:36 EDT FTAC Emerald Acquisition postpones special meeting - FTAC Emerald Acquisition announces that the special meeting in lieu of annual meeting of stockholders scheduled to be held on September 18, 2023 at 4:30 pm Eastern Time will be postponed until 4:30 pm Eastern Time on Tuesday, September 19. The Meeting is being held for the purposes of considering and voting on an extension amendment to the Company's Amended and Restated Certificate of Incorporation, an extension amendment to the Investment Management Trust Agreement and an Adjournment Proposal, each as described in the Company's amended definitive proxy statement filed with the Securities and Exchange Commission on August 31, 2023. The price for any shares of Class A common stock properly redeemed in connection with the Meeting is estimated to be approximately $10.47 per share.

08:35 EDT AgriFORCE Growing Systems announces launch, purchase of Hydroxyl device - AgriFORCE Growing Systems announced the commercial launch and first purchase order for its AgriFORCE-RCS Hydroxyl device with Commercializadora DESICO, a leading distributor of AC, heating and air ventilation systems. AgriFORCE Interim CEO, Richard Wong commented, "This first purchase order marks a major milestone in the commercial rollout of the AgriFORCE-RCS Hydroxyl devices. We have conducted extensive analysis and worked closely with Radical Clean Solutions Ltd, the inventor and developer of the technology, to customize the technology for the specific needs of customers in the controlled environment agriculture (CEA) and food manufacturing industries. The patent-pending system seeks out and destroys both airborne and surface-based mold, bacteria, virus, and VOCs, as well as other pathogens and pollutants in real-time. By reducing mold and VOCs, we expect to have a dramatic impact on the bottom line of our customers through reducing food spoilage. In fact, according to Food and Agricultural Organization (FAO), it is estimated that mycotoxin (mold) affects nearly 25% of the world's crops. We believe this is just the first of many orders with DESICO and in the Mexico market with vast acres of greenhouses as potential clients, and a large food manufacturing industry. We currently have units in testing within greenhouses in the United States and expect test results soon. We also look forward to expanding into new markets around the world."

08:34 EDT Kopin receives $3.4M follow-on order for F-35 program - Kopin (KOPN) announced it has received a $3.4M follow-on order for its high-brightness liquid crystal display for the F-35 Joint Strike Fighter program. With the F-35 scheduled for production through 2030, Kopin expects additional orders over the life of the program.

08:34 EDT Trust Stamp announces technology for global Alternative to Detention market - Trust Stamp announced the launch of its Tap-In Band, a wrist-worn, tamper resistant, hypoallergenic NFC band that facilitates discrete check-in by, and communication with, participants in community based supervision programs. The Tap-In Band leverages the GPS and NFC technologies in the user's own mobile phone and allows the user to verify their well-being and location by tapping the band to the phone, gaining direct access to a personalized web portal with messaging and two-way audio visual communications. Gareth Genner, Trust Stamp's Chief Executive Officer said, "The Tap-In Band is the result of three years of market discovery and development and is a game-changer. The band is battery-free and has a fitness band-styled design that provides secure authentication without imposing embarrassment or discomfort. We are not publicly releasing images of the customizable aesthetic design but I will say that the Band is available in a variety of colors with optional design features that ensure that the underlying use-case is not obvious to an onlooker.

08:32 EDT Cantex Pharmaceuticals, Lenox Hill initiate Phase 2 study of azeliragon - Cantex Pharmaceuticals and Lenox Hill Hospital's Department of Neurological Surgery announced the initiation of a Phase 2 study to assess the safety and effectiveness of azeliragon in combination with radiation therapy as a treatment for newly diagnosed unmethylated glioblastoma. Azeliragon is an orally administered capsule, taken once daily, that inhibits interactions of the receptor for advanced glycation end products with certain ligands, including HMGB1 and S100 proteins in the tumor microenvironment. Azeliragon was discovered by and originally under development for Alzheimer's disease by vTv Therapeutics from whom Cantex licensed worldwide rights to azeliragon.

08:31 EDT Enovis debuts new foot, ankle products at AOFAS Annual Meeting - Enovis Corporation announced it will showcase new products from its recent acquisitions of Novastep and the external fixation assets of D.N.E., LLC, along with its new, organically developed Evolve34 Lapidus Instrumentation, and the new "STAR+ Experience," Enovis' Total Ankle System plus patient specific instrumentation, at the American Orthopaedic Foot & Ankle Society(R) annual meeting in Louisville, Kentucky from September 20-23, 2023. Other offerings being showcased for the first time will be Evolve34, a bunion solution for Lapidus correction that allows surgeons to dial in deformity correction and select a hardware construct specific for the patient's needs. Additionally, Enovis will be introducing the all new EF1 External Fixation product line, complimenting the flagship DynaNail and DynaClip offerings in the hindfoot segment.

08:28 EDT PLDT selects Amdocs for cloud migration, modernization project - Amdocs (DOX) has been selected by PLDT (PHI) and its wireless subsidiary Smart Communications, to accelerate their cloud modernization on Amazon Web Services/ PLDT is modernizing its IT infrastructure to improve business agility and respond faster to market dynamics, driving innovations and delivering an enhanced connected customer experience. In this multi-year collaboration, Amdocs will seamlessly migrate select business-critical systems and applications to AWS. Amdocs will provide cloud strategy, planning consultancy, and cloud security and operations services, using its new artificial intelligence-driven cloud operations platform. Hosted on AWS, the platform will help PLDT and Smart optimize and scale infrastructure performance and resources as needed. This holistic approach to cloud adoption and management is designed to bring PLDT and Smart increased operational resilience, leading to business agility and innovation, and continuity of services.

08:25 EDT Green Plains Partners trading halted, news pending

08:22 EDT Joby Aviation to locate first scaled aircraft production facility in Dayton - Joby Aviation, which is developing electric vertical take-off and landing, or eVTOL, aircraft for commercial passenger service, announced it plans to locate its first scaled aircraft production facility in Dayton, Ohio. "Joby plans to build a facility capable of delivering up to 500 aircraft per year at the Dayton International Airport, supporting up to 2,000 jobs. The 140-acre site it has selected has the potential to support significant further growth over time, providing enough land to build up to two million square feet of manufacturing space. Construction of the scaled Ohio facility is expected to start in 2024 and it is expected to come online in 2025. Joby plans to use existing nearby buildings to begin near-term operations. The State of Ohio, JobsOhio and local political subdivisions have offered incentives and benefits of up to $325M to support the development of the facility, while Joby plans to invest up to $500M as it scales operations at the site. Joby is also announcing today that it has been invited by the U.S. Department of Energy to submit a Part II Application for financing under the Title XVII Loan Guarantee Program, which provides access to low-interest loans for clean energy projects and would support the scaling of the facility. Joby's long-term investor, Toyota, who worked with Joby on the design and successful launch of the company's Pilot Production Line in Marina, California, plans to continue to advise Joby as it prepares for scaled production of its commercial passenger air taxi in Ohio," the company stated. "Joby plans to start hiring in the coming months, with early roles expected to focus on the build out of the scaled facility and the machining of parts that will initially be incorporated into Joby's California low-volume production line," the company added.

08:20 EDT Sidus secures position on SpaceX's upcoming Bandwagon mission - Carol Craig ,Sidus Founder & CEO of Sidus Space said in part in a letter to shareholders: "Following this morning's announcement regarding the reallocation of two LizzieSats to launch on an upcoming Bandwagon mission with SpaceX, I want to explain in greater detail what this means for Sidus. In addition, I will provide an update on our plan to regain compliance on the Nasdaq Capital Market as we focus on growing our business, increasing gross margins, and building value for our shareholders....we announced that Sidus secured a position on SpaceX's upcoming Bandwagon Mission, reallocating two of our AI-driven LizzieSat satellites...As mentioned in the release this morning, we made the decision to capitalize on SpaceX's recent announcement to launch Bandwagon missions after evaluating the potential increased revenue opportunity tied to placing multiple LizzieSats in dissimilar orbits. This change will enable us to capture higher revenue generating data by covering more populated areas while also increasing our payload and data customers. We believe that, in combination with the inclusion of additional sensors and enhanced AI capabilities, the new orbits add value as we get closer to initiating these launches and developing new, high-margin business lines...Both LizzieSat Bandwagon missions will include sensors utilizing co-incident or simultaneous data collection to capture still images, hyperspectral and multispectral images, AIS, and wide-area-spectral imaging...We believe that our FeatherEdge AI, working in concert with these additional sensors and combined with the addition of an Equatorial Orbit, will allow Sidus to provide unparalleled data service to our customers. While we initially planned to launch the first LizzieSat on Transporter-9 in Q4 2023, we made the strategic decision to adjust our launch manifest in order to enhance the capacity of our constellation deployment. The updated schedule will expand this mission to target a first launch in the first quarter 2024, with a current target launch date of February 2024, and two LizzieSats on a Bandwagon mission in the second quarter of 2024. Additionally, we plan to have a minimum of five LizzieSats on orbit in the Company's constellation by the end of the second quarter of 2024. Finally, I would like to address our plan to regain compliance on the Nasdaq Capital Market..In early September, we requested, and have now been granted, an additional 180-day extension to the period allowed to regain compliance. This extension will give us until March 11, 2024 to increase our share price above $1.00, and therefore regain compliance.

08:18 EDT Camtek to acquire FormFactor's FRT Metrology business for $100M in cash - Camtek (CAMT), together with FormFactor (FORM), are pleased to announce that they have entered into an agreement for the acquisition by Camtek of FormFactor's FRT Metrology business for $100M in cash, subject to customary purchase price adjustments. FRT, headquartered in Bergisch Gladbach, Germany, is a leading supplier of high-precision metrology solutions for the Advanced Packaging and Silicon Carbide markets. The transaction is expected to close in Q4 2023, subject to the satisfaction of customary closing conditions. "We welcome FRT and its employees to the Camtek family," said Mr. Rafi Amit, Camtek's CEO. "We expect this acquisition to solidify Camtek's leading market position and contribute over $30 million to the annual revenues in 2024 and be accretive within 12 months following the acquisition. Beyond the immediate financial contribution, we expect further synergies that will contribute to Camtek's overall growth prospects in 2024 and beyond. We look forward to capturing a larger share of the unique growth opportunities ahead of us."

08:17 EDT DocGo appoints Lee Bienstock as CEO - DocGo announced that its board of directors has appointed Lee Bienstock, who most recently served as the company's president and COO, to the role of CEO, effective September 15. Bienstock joined DocGo in 2022 after ten years at Google, where he most recently served as Global Head of Enterprise Partnerships for Devices and Services.

08:16 EDT Smart Share Global announces extension of share repurchase program - Smart Share Global announced the extension of its share repurchase program and changes to management team. The Company's board of directors authorized a further 12-month extension to its existing share repurchase program through September 27, 2024. The Share Repurchase Program was originally approved by the Board on September 28, 2021, under which the Company may repurchase up to US$50.0 million of its shares through September 27, 2022. On September 28, 2022, the Company announced that the Share Repurchase Program was extended through September 27, 2023 as authorized by the Board. As of September 15, 2023, the Company had cumulatively repurchased approximately US$5.7 million of its shares under the Share Repurchase Program.

08:14 EDT Tingo Group appoints interim co-Chief Executives , Independent Director - Tingo Group (TIO) announced the appointments of Dozy Mmobuosi and Kenneth Denos each as interim co-Chief Executive Officers, following the decision by Darren Mercer to retire to spend time with his young family and to coincide with his milestone birthday yesterday. As the Company announced on May 10, 2022, Mercer planned to step down as Chief Executive following the merger of MICT and Tingo, Inc. under the original merger transaction. That move, however, was postponed under the new merger structure, which completed on November 30, 2022, and then delayed further by the Investigation. As the founder and visionary of both Tingo Foods and Tingo Mobile Limited, which has become one of Africa's leading agri-fintech companies over the past 23 years, Mmobuosi is uniquely positioned to lead the Company, develop it further and provide continuity, while the Company completes a global search for a permanent world-class Chief Executive Officer, who has relevant expertise and experience. Denos has served as a director of Tingo since its acquisition of Tingo Mobile in November 2022, and an executive of Tingo Mobile's prior parent company, Agri Fintech Holdings since August 2021. In addition, the Company is pleased to appoint Jamal Kurshid as an independent member of the Board of Directors. Mr. Kurshid brings more than 20 years of investment banking experience with several leading financial institutions including Goldman Sachs (GS).

08:11 EDT Myriad , MSK collaborate to study use of minimal residual disease testing - Myriad Genetics announced a collaboration with Memorial Sloan Kettering Cancer Center, MSK, to study the use of minimal residual disease testing in breast cancer. The research project will use Myriad's MRD testing platform, a tumor-informed high-definition assay that uses whole-genome sequencing to achieve high sensitivity and specificity for circulating tumor DNA. Myriad is working together with Pedram Razavi, MD, PhD, a breast medical oncologist and Director of Liquid Biopsy & Genomics at MSK Global Biomarker Development Program. The MSK research team will investigate the use of MRD testing for patients in two breast cancer cohorts. The first will be in a metastatic patient population treated with CDK4/6 inhibitors and will evaluate the ability of MRD testing to predict treatment response. The second will be focused on the neoadjuvant setting and will assess the association of MRD testing with chemotherapy treatment response.

08:10 EDT GE HealthCare awarded $44M grant to develop AI ultrasound tech - GE HealthCare announced it received a grant from the Bill & Melinda Gates Foundation for more than $44M to create user-friendly, artificial intelligence assisted ultrasound imaging auto-assessment tools. These tools will seek to aid healthcare professionals-even those without specialized training or experience with ultrasound-with clinical decision information to support more effective obstetric and lung screening ultrasound scans across maternal and fetal care as well as pediatric lung health, with a goal of expanding access to low-and-middle income countries and across diverse sites of care. Caption Health, a leader in medical AI acquired by GE HealthCare in February 2023, will design this technology to run across a range of ultrasound devices and probes, including lower-cost handheld devices.

08:08 EDT Rani Therapeutics initiates Phase 1 study of RT-111 - Rani Therapeutics (RANI) announced the initiation of a Phase 1 clinical trial to evaluate the safety and tolerability of RT-111, an orally administered RaniPillGO capsule containing an ustekinumab biosimilar, CT-P43. Topline results from this study are expected early in the first quarter of 2024. Ustekinumab is a human IgG1 monoclonal antibody that binds with specificity to the p40 protein subunit used by both the interleukin-12 and interleukin-23 cytokines, and is marketed in the United States by Janssen (JNJ) as STELARA. Currently, ustekinumab is available only as a subcutaneous injection. "We are thrilled to announce the advancement of RT-111 into the clinic, an important milestone for Rani which brings us one step closer to our goal of making oral biologics a reality for patients with autoimmune diseases," said Talat Imran, Chief Executive Officer of Rani. "Psoriasis, psoriatic arthritis and other autoimmune conditions are chronic diseases that can require regular, painful injections that are burdensome for patients. RT-111 is a convenient, oral delivery of ustekinumab via the RaniPill capsule. Moreover, because the RaniPill capsule technology is a drug-agnostic delivery platform, RT-111 also represents a broader opportunity to potentially replace other injectable-only monoclonal antibodies and large molecules with an oral alternative."

08:06 EDT Skyward Specialty Insurance announces individual provider coverage - Skyward Specialty Insurance Group is expanding its coverages in the healthcare sector adding a new solution catering to the distinct needs of E&S individual providers, including physicians. The healthcare landscape continues to present new challenges and opportunities for healthcare professionals, especially for individual providers and physicians. The demand for this type of coverage has outpaced the insurance market's capacity and capabilities, resulting in a growing need for bespoke solutions for healthcare professionals. Additionally, the nation is facing an unprecedented shortage of individual providers and physicians with fewer healthcare professionals entering the market and experienced professionals leaving the market due to costly malpractice suits and rising costs of litigation. Many practitioners have difficulty obtaining tailored solutions due to their history and often are left with limited coverage options and even fewer carriers to turn to. The Company's newly named Healthcare Solutions underwriting unit, formerly known as Allied Health, was established in 2021. Since that time the Company has taken bold steps to reach underserved markets beyond the traditional Allied Health scope. The Healthcare Solutions team will begin accepting submissions for Individual Provider coverage on Monday, October 2.

08:06 EDT MariaDB receives unsolicited non-binding proposal from Runa Capital II - The Board of MariaDB notes the announcement made by Runa Capital II on September 15, and confirms that it has received an unsolicited non-binding indicative proposal from Runa Capital II GP as general partner of Runa Capital Fund II on behalf of itself and its other investment affiliates to acquire 100% of the issued ordinary shares of the Company other than those shares already owned by Runa. The Board of MariaDB is reviewing and taking advice regarding the Possible Offer. The Possible Offer may or may not lead to an offer being made for the entire share capital of the Company. There can be no certainty that any offer will be made. A further announcement will be made if and when appropriate.

08:05 EDT Research Solutions announces cooperation agreement with investor group - Research Solutions announced that it has entered into a cooperation agreement with Peter Derycz, Bristol Investment Fund, Ltd., Bristol Capital Advisors, LLC and Paul Kessler, which collectively own 5,921,930 shares of the company's outstanding common stock. Under the terms of the Cooperation Agreement, Derycz's employment will be terminated without cause, and he will resign from the company's board of directors and all committees upon which he currently serves, and from any positions that he holds with the company and any of its subsidiaries. To fill the vacancy resulting from Dercyz's departure, the company will appoint an independent director to the Board that is mutually agreed upon by the parties. Additionally, the Investor Group has agreed to withdraw its notice of intent to nominate director candidates for election at the company's 2023 Annual Meeting of Shareholders and cease all solicitations of proxies and other activities in connection with the Annual Meeting. During the term of the Cooperation Agreement, the Investor Group has also agreed to customary standstill provisions and voting commitments. Further, the company and the Investor Group have each agreed to a mutual general release of claims with respect to the other party.

08:04 EDT Dynex Capital acquires models, proprietary data developed by Contingent Macro - Dynex Capital announced Terrence Connelly has joined Dynex to spearhead its strategic initiatives and research efforts. Dynex has also acquired the models and proprietary data developed by Contingent Macro under Connelly's leadership. These assets will play a role in leveraging evolving technologies to enhance Dynex's capabilities and enable the company to maintain its investment edge and risk management in complex global markets.

08:04 EDT MediGene selects lead candidate for MDG2011 therapy - Medigene has selected its lead candidate for MDG2011, a T cell receptor engineered T cell therapy targeting KRAS G12V with HLA-A*11 and being developed in combination with the Company's PD1-41BB costimulatory switch protein technology. Medigene's end-to-end platform, has successfully generated not one but three KRAS G12V-HLA-A*11 TCRs, each with distinct, multiple HLA-A*11 subtype recognition patterns that exceed the Company's selection criteria for highly specific, sensitive and potentially safer TCRs. After deploying Medigene's proprietary algorithms for evaluation of the unique characteristics of each of the 3S TCRs, including peptide specificity, tumor cell recognition and off-target toxicity, the Company has prioritized one of the 3S TCRs as the lead to move forward to the pre-clinical stage for Medigene's MDG2011 program. The Company's E2E platform continues to generate 3S TCRs with unique attributes that add additional dimensions to the potential of Medigene's TCR-T therapies as well as to confirm the Company's discovery research efforts. One such attribute is the identification of a TCR candidate demonstrating bi-specific recognition for both the KRAS G12V and G12C mutations. Directed TCR discovery efforts in the future will enable identification of an optimal KRAS G12C-specific TCR lead. The two remaining KRAS G12V-A11 TCRs not selected for the MDG2011 program will be added to Medigene's KRAS TCR library for potential future programs that align the product vision with the profile of each TCR. Patents have been filed for each of the three TCRs. MDG2011 is the first program of Medigene's pipeline expansion into a library of neoantigens including, but not limited to: KRAS G12V-HLA-A*11; KRAS G12V-HLA-A*03; KRAS G12D-HLA-A*11; These TCRs will be combined with the PD1-41BB and/or the CD40L-CD28 costimulatory switch proteins to enhance penetration, proliferation, persistence and enhanced cytotoxic function of Medigene's TCR-T cells while mitigating the immunosuppressive effects of the tumor microenvironment.

08:02 EDT CME Group to launch Cobalt Hydroxide futures on October 23 - CME Group announced that it will launch Cobalt Hydroxide futures on October 23, pending all relevant regulatory reviews. This is the fourth battery metals futures contract CME Group has launched in response to evolving hedging needs within the rapidly growing electric vehicle space.

08:02 EDT Tracon announces ENVASARC Phase 2 trial exceeded futility threshold - TRACON Pharmaceuticals announced that the ENVASARC Phase 2 pivotal trial more than satisfied the futility threshold of 3 responses out of 46 based on the results of the second and final mandated independent data monitoring committee (IDMC) efficacy review, and the trial will continue as planned. The IDMC reviewed interim safety and efficacy data from 46 patients enrolled into cohort C of treatment with single agent envafolimab who completed two on-treatment scans. The objective response rate in the initial 46 patients treated with single agent envafolimab was 13% by investigator review and 8.7% by blinded independent central review. The ORR assessed by BICR, all of which were confirmed responses, more than satisfied the prespecified futility rule and envafolimab monotherapy was generally well tolerated. Median duration of response by BICR was greater than six months. The primary endpoint of the study is achievement of an ORR in nine of 80 patients treated with envafolimab by BICR and median duration of response of greater than six months is a key secondary endpoint. "Envafolimab continues to demonstrate durable single agent activity and has been generally well tolerated," said James Freddo, M.D., TRACON's Chief Medical Officer. "Our goal is the demonstration of nine objective responses by BICR in the 80 patient cohort of single agent envafolimab treatment."

07:56 EDT Nikola names Mary Chan as COO, effective October 9 - Nikola (NKLA) announced the appointment of Mary Chan as COO, effective October 9. Chan was a Managing Partner at VectoIQ, where she assisted with the public launch of Nikola Corporation. She served as President of the Global Connected Consumer group at General Motors (GM) and built the next generation of connected infotainment products and OnStar broadband data services. She led the industry's first launch of 4G LTE connectivity across GM's global brands in the U.S., China, Europe, and Mexico.

07:46 EDT Jacobs awarded contract for global logistics hub in Saudi Arabia - Jacobs has been appointed by NEOM Company as the lead design consultant for the Port of NEOM redevelopment project in northwest Saudi Arabia. The project in NEOM's new industrial city Oxagon, will transform the existing facility into a net zero, next-generation global logistics hub. The world's first integrated port and supply chain system is expected to be fully automated and operate on 100% renewable energy. The design and construction will incorporate a range of sustainability initiatives, including recovering and reusing materials and structures where possible and using low-carbon steel frames to construct quay walls.

07:39 EDT FSD Pharma announces interim results from FIH trial of Lucid-MS - FSD Pharma announced that an interim report has been received for the first-in-human single ascending dose Phase I clinical trial evaluating the Company's novel drug candidate Lucid-21-302, an orally-administered treatment for Multiple Sclerosis. This interim blinded report was issued on August 17, 2023 for the first 4 cohorts, with an addendum report describing the results of the fifth cohort due by the end of the month. The report, issued by Biopharma Services Inc. as the clinical research organization under contract to FSD, states that "Lucid-21-302 was demonstrated to be safe and well-tolerated in single oral doses in healthy volunteers. Individual concentrations and PK parameters of Cohorts 1 to 4 are very encouraging for further development activity."

07:35 EDT Aehr Test receives order from new customer for FOX-NP multi-wafer test - Aehr Test Systems announced it has received an initial customer order for a FOX-NP wafer level test and burn-in system, multiple WaferPak Contactors, and a FOX WaferPak Aligner to be used for engineering, qualification, and small lot production wafer level test and burn-in of their silicon carbide devices. The customer is a US-based multibillion-dollar semiconductor supplier serving several markets including automotive, computing, consumer, energy, industrial, and medical. The FOX-NP system, including the FOX WaferPak Aligner and initial WaferPaks are scheduled per the customer's requested accelerated schedule to ship by the end of the calendar year 2023. Gayn Erickson, President and CEO of Aehr Test Systems, commented, "We are very excited that after conducting a detailed financial evaluation and multiple onsite visits to Aehr's application lab, this new customer selected our FOX-P solution for engineering, qualification, and production of their silicon carbide power devices. This evaluation included cost of ownership and system throughput, as well as device test, burn-in, and stabilization coverage. As their production capacity increases, they told us that they will quickly move to our FOX-XP multi-wafer test and burn-in systems for high-volume production. In addition to the automotive electric vehicle device opportunity, this customer in particular sees the enormous opportunity for silicon carbide power devices in industrial, solar, and other power applications."

07:33 EDT ContraFect announces submission of IND application to FDA for CF-370 - ContraFect announces that it submitted an Investigational New Drug, IND, application to the U.S. Food and Drug Administration, FDA, on September 15, 2023. The IND application supports a proposed indication for its intravenous antibacterial agent, CF-370, for treatment of hospital-acquired bacterial pneumonia, HABP, and ventilator-associated bacterial pneumonia, VABP. "Today's announcement is an important milestone for our CF-370 program. Globally, there are millions of deaths each year associated with infections caused by antibiotic-resistant Gram-negative bacteria. To be able to advance CF-370, a novel therapeutic candidate with the potential to reduce this seemingly insurmountable burden, into the clinic provides hope for patients suffering and dying in our ICUs every day, many of whom are the most vulnerable from a medical perspective, due to their age, recent surgery or having underlying immunosuppressive conditions," said Roger Pomerantz, MD, President, Chief Executive Officer, and Chairman of ContraFect. "I want to thank our dedicated employees, our extended team of consultants and our shareholders, for bringing our second program into clinical development. We look forward to initiating Phase 1 First-in-Human studies in the US later this year."

07:31 EDT Reunion Neuroscience receives FDA clearance of IND application for RE104 study - Reunion Neuroscience announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application to initiate a Phase 2 study of RE104, a novel serotonergic psychedelic compound, for the treatment of postpartum depression. The Phase 2 study, the RECONNECT Trial, is a multicenter, randomized, double-blind, parallel-group, active-dose placebo-controlled study, which will evaluate the safety and efficacy of a single subcutaneous dose of RE104 in adult female patients with PPD. The study is expected to begin in Q4 2023 with a targeted data readout in late 2024.

07:23 EDT GameSquare announces $10M working capital line of credit - GameSquare Holdings announced a $10M working capital line of credit with SLR Capital Partners that matures in September 2026.

07:20 EDT Virios Therapeutics terminates at-the-market sales agreement - Virios Therapeutics provided notice of termination of the Capital on Demand Sales Agreement entered into between the Company and JonesTrading Institutional Services LLC on July 14, 2023. The Company has initiated the 10-day termination process under the Sales Agreement, with the official termination taking effect on September 28, 2023. The Company will make no sales under the Sales Agreement during this period. The Company's management team is currently focusing its attention on short-to-medium term operational priorities that are within the current operating budget, including: Providing an additional grant to conduct a second Long-COVID study with the Bateman Horne Center. This new study is planned as a double-blinded, placebo-controlled assessment of IMC-2 in Long-COVID. Exploring opportunities for non-dilutive funding to support further IMC-2 development. Preparing for a Pre-Investigational New Drug meeting with the Food & Drug Administration to discuss IMC-2 as a potential treatment for Long-COVID and other fatigue related disorders. Prosecuting a patent application covering the treatment of Long-COVID and Alzheimer's disease with combination antiviral formulations. Exploration of potential partnerships for both the fibromyalgia and Long-COVID Programs.

07:15 EDT DocGo CEO Anthony Capone resigns due to 'personal reasons' - In a regulatory filing on Friday night, DocGo disclosed that on September 15, effective immediately, Anthony Capone resigned as the Chief Executive Officer of the company and from all other positions with the company "due to personal reasons." On September 15, the board of directors of the company appointed Lee Bienstock, the company's current President and Chief Operating Officer, as the CEO of the company, effective immediately. "The position of President and Chief Operating Officer will remain vacant," the filing stated.

07:13 EDT B2Gold provides update for Goose Project in Nunavut, Canada - B2Gold provides a construction update on the Goose Project, located in the 100% owned Back River Gold District in Nunavut, Canada. B2Gold acquired the Back River Gold District as part of the acquisition of Sabina Gold & Silver in April 2023. Goose Project Update Highlights: Goose Project on schedule for first gold pour in Q1 2025; Construction capital expenditures remain in line with June 2023 estimate of C$800 million; Accelerated underground mining plan adopted to increase average gold production in the first five years to over 300,000 ounces per year; Concrete and steel work in the mill area progressing ahead of schedule; Phase 1 of the accommodation complex opened in July 2023; Earthworks necessary to extend airstrip to be completed in September 2023; Winter ice road preparations are well underway; 11,000 meters of drilling over 44 drill holes has been completed to date in 2023 at Back River.

07:12 EDT BioCryst announces INESSS recommended public reimbursement for ORLADEYO - BioCryst Pharmaceuticals announced that the Institut national d'excellence en sante et services sociaux, INESSS, has issued a positive recommendation for PrORLADEYO to be reimbursed for the prevention of hereditary angioedema, HAE, attacks in adults and pediatric patients 12 years of age and older in Quebec. "We are committed to bringing ORLADEYO to as many Canadians living with HAE as possible. This announcement from INESSS, which follows the positive recommendation from CADTH earlier this year, takes us one step closer to making our oral, once-daily therapy available to Canadians who are in need of a new option to help improve control of their HAE attacks," said Anand Janack, vice president and general manager of BioCryst Canada.

07:09 EDT Tonix Pharmaceuticals presents non-clinical studies on TNX-1900 - Tonix Pharmaceuticals announced that David Yeomans, Ph.D. presented data relevant to the proposed mechanism of TNX-1900 in treating chronic migraine in a poster and an oral presentation at the 2023 International Headache Congress, being held September 14-17, 2023, in Seoul, South Korea. The poster and oral presentation titled, "Human trigeminal ganglia possess oxytocin receptors on CGRP positive neurons: expression increased by inflammation," include research sponsored by and licensed to Tonix Pharmaceuticals. The presentations show that oxytocin receptors are co-expressed with calcitonin gene-related peptide on human trigeminal ganglia neurons, which is similar to Professor Yeomans' previous findings in animal trigeminal ganglia. The inflammatory cytokine IL-6 upregulated expression of oxytocin receptors on human trigeminal neurons, consistent with the previously observed impact of inflammation on the potency of oxytocin. In animals, oxytocin has been shown to functionally inhibit the excitability of trigeminal neurons, which is consistent with oxytocin inhibiting the release of CGRP at trigeminal nerve terminals.

07:08 EDT Eloxx reports independent confirmation of TEM assessment results - Eloxx Pharmaceuticals reported additional independent confirmation on the positive TEM assessment results from its proof-of-concept Phase 2 open-label clinical trial of ELX-02 for the treatment of Alport syndrome after eight weeks of treatment. Visual assessment of TEM images from kidney biopsies showed an improvement in foot process effacement in all three treated patients consistent with disease regression. Additional independent confirmation has now been reported. The qualitative assessment of images of pre- and post-treatment kidney biopsies from the three patients in the Phase 2 clinical trial noted: Patient 4401-01 and Patient 4401-02: All images showed more regions of glomerular basement membranes in post-treatment biopsies covered by intact foot processes, consistent with partial improvement of podocyte injury in those biopsies. As previously announced, Patient 4401-02 achieved remission based on Urine-Protein Creatine ratio. Patient 4402-01: Post-treatment images showed wider areas of intact foot processes compared with either pre- or post-treatment images for Patient 4401-01 and Patient 4401-02. These findings are generally consistent with previous assessments, providing stronger evidence of protein restoration and the disease modifying effect of ELX-02 and potential for improvement in proteinuria with longer duration of treatment.

07:07 EDT Galera Therapeutics schedules Type A meeting with FDA for avasopasem - Galera Therapeutics announced that a Type A Meeting has been scheduled for September 28, 2023 with the U.S. Food and Drug Administration regarding the Complete Response Letter received for the Company's New Drug Application for avasopasem manganese. The FDA is expected to issue written meeting minutes approximately 30 days following the meeting. The Company intends to gain an understanding from the FDA of its evaluation of avasopasem for radiotherapy-induced severe oral mucositis in patients with head and neck cancer undergoing standard-of-care treatment and next steps to support an NDA resubmission. The Type A Meeting is the highest priority classification of meeting that the FDA grants to NDA sponsors.

07:07 EDT Nevro announces publication of data from study of 10 kHz Therapy - Nevro announced the publication of new data validating the health economic benefits of 10 kHz Therapy, Nevro's proprietary high-frequency,10 kHz spinal cord stimulation therapy. This data was derived from studies and analyses that evaluated health care utilization - doctor visits, medical procedures, tests and emergency room visits, and medication costs - and related cost data, including inpatient and outpatient service, medication, and out-of-pocket costs. Results from a study evaluating the effect of 10 kHz Therapy on resources needed to manage and care for patients with painful diabetic neuropathy were published in the Journal of Managed Care & Specialty Pharmacy. Study participants were randomly assigned to 10 kHz Therapy or conventional medical management, with outcomes measured at six months. Results showed that the 10 kHz Therapy arm experienced about half the mean rate of hospitalizations per patient compared to the CMM group (0.08 vs. 0.15). Additionally, the CMM group's total healthcare costs per patient were approximately 51% higher compared to the 10 kHz Therapy group (equivalent to a mean annual cost per patient of $9,532 vs. $6,300).

07:06 EDT Black Rifle Coffee appoints Danya Kennedy as Chief Revenue Officer - Black Rifle Coffee announced the appointment of Danya Kennedy as Chief Revenue Officer. In her role, Danya will support the Company's efforts to further build on its strong brand momentum and drive profitable, sustainable growth across channels. "Danya brings an immense amount of experience to BRCC, and I am excited to welcome her to our executive team," said Evan Hafer, Founder and Co-CEO of Black Rifle Coffee. "As we continue to strengthen our management team, Danya's experience will be incredibly beneficial as we look to expand to new markets and continue to build towards sustainable, profitable growth over the long term."

07:05 EDT Essa Pharma initiates Phase 2 study of masofaniten/enzalutamide combo - Essa Pharma (EPIX) announced the initiation of the Phase 2 portion of its Phase 1/2 study evaluating its lead candidate, masofaniten, a first-in-class N-terminal domain androgen receptor inhibitor, in combination with Astellas (ALPMY) and Pfizer's (PFE) antiandrogen enzalutamide in patients with metastatic castration-resistant prostate cancer naive to second-generation antiandrogens. Updated results from the first four cohorts of patients from the Phase 1 dose escalation portion of the Phase 1/2 study have been selected for a poster presentation at the upcoming European Society of Medical Oncology Congress taking place October 20-24, 2023, in Madrid, Spain.

07:04 EDT EyePoint reports inducement grants under Nasdaq listing rule - EyePoint Pharmaceuticals announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 4,000 shares of EyePoint Pharmaceuticals common stock to two new employees. The stock options were granted on September 15, 2023. The grants were approved by the Compensation Committee and made as an inducement material to each employee entering into employment with EyePoint Pharmaceuticals in accordance with NASDAQ Listing Rule 5635(c)(4). The option awards have an exercise price of $10.48 per share, the closing price of EyePoint Pharmaceuticals' common stock on September 15, 2023. The options have a ten-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee's date of grant and the remainder vesting in equal monthly installments over the following three years. Vesting of the options is subject to the employee's continued service with EyePoint Pharmaceuticals through the applicable vesting dates.

07:03 EDT CN launches Rail Safety Week awareness campaign - CN launched its annual Rail Safety Week awareness campaign. The Company joins groups across North America to raise awareness of the danger of unsafe behaviour around railway property. From September 18-24, CN Police Service, along with many CN employees, will share important rail safety messages in communities across CN's network to help prevent accidents and injuries.

07:02 EDT Black Diamond Therapeutics appoints Velleca as CEO - Black Diamond Therapeutics announced that current Chairman of the Board, Mark Velleca, M.D., Ph.D., has been appointed as Chief Executive Officer, CEO, effective immediately. Dr. Velleca succeeds Company CEO and co-founder, David M. Epstein, Ph.D., who has stepped down and will continue to serve on the Board of Directors of the Company. Dr. Velleca joined the Board of Directors of Black Diamond in 2021 and became Chairman of the Board in 2022.

07:01 EDT Kymera Therapeutics receives U.S. FDA FTD for KT-333 - Kymera Therapeutics anounced that the U.S. Food and Drug Administration, FDA, has granted Fast Track designation , FTD, to KT-333 for the treatment of R/R Cutaneous T-cell Lymphoma, CTCL, and R/R Peripheral T-cell Lymphoma, PTCL. "The KT-333 Fast Track designation highlights the promise of degrading STAT3, a protein that has historically been undruggable, for the treatment of patients with CTCL and PTCL," said Jared Gollob, MD, Chief Medical Officer, Kymera Therapeutics. "We look forward to providing an update on the KT-333 Phase 1 clinical trial later this year, including initial evaluation of its antitumor activity in the target patient populations, and to working with the lymphoma community to rapidly advance this first-in-class heterobifunctional degrader in CTCL and PTCL in addition to exploring its potential in other cancers."

06:48 EDT Novartis' Sandoz receives positive CHMP opinion for biosimilar trastuzumab - Sandoz, a Novartis division, announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency has adopted a positive opinion recommending marketing authorization for their biosimilar trastuzumab, developed by EirGenix, Inc. The positive opinion for Sandoz trastuzumab, a monoclonal antibody, covers treatment of human epidermal growth factor receptor 2 positive breast cancer and metastatic gastric cancers, the same indications as approved by EMA for the reference biologic.

06:34 EDT Hut 8 Mining provides update on USBTC combination - Hut 8 Mining announced that, in connection with its previously announced business combination with U.S. Data Mining Group, or USBTC, to be effected by way of a court-approved plan of arrangement under the Business Corporations Act, the Supreme Court of British Columbia has issued a final order approving the Arrangement. Pursuant to the Transaction, Hut 8 and USBTC will combine in an all-stock merger of equals and the combined company will be named Hut 8 Corp. and be a U.S.-domiciled entity. Closing of the transaction remains subject to certain conditions, including USBTC's registration statement becoming effective, the approval of USBTC's stockholders, and other closing conditions customary in transactions of this nature. If all necessary conditions to the completion of the transaction are satisfied or waived, it is expected that the Transaction will be completed during the fourth quarter of 2023. New Hut intends to list its shares on Nasdaq and the TSX under the trading symbol "HUT" following the completion of the Transaction, subject to the approval of Nasdaq and the TSX. The company reminds registered shareholders to promptly deliver a duly completed and signed letter of transmittal to Computershare Investor Services Inc., in order to receive their shares of New Hut common stock upon closing of the Transaction.

06:33 EDT Nxu Inc. announces first megawatt+ charging site along major highway corridor - Nxu Inc. is under contract to purchase the site for its first deployment of megawatt+ charging, in Quartzsite, Ariz. Located on a major highway corridor immediately off exit 19 on Interstate 10, the Nxu One Megawatt+ Charging location will provide a much-needed charging experience for the growing number of consumer and commercial EVs regularly traveling on this major freeway between Phoenix and Los Angeles. The Nxu One Charging System is the only universal, dual-technology solution available for public charging. With a liquid-cooled charging handle, it is designed to support up to 4.5MW of bi-directional DC power and up to 50kW of bi-directional AC power. Nxu One adapts to the vehicle, charging as fast and as powerful as the vehicle will allow - whether that's a Chevy Bolt or an EV semi. A seamless cloud experience provides charging monitoring and payment solutions.

06:31 EDT ImmunoGen names Lauren White as CFO - ImmunoGen (IMGN) announced that Lauren White has been appointed Senior Vice President and CFO. White has over 20 years of international experience in corporate finance, strategic partnering, accounting, and investor relations. She joins ImmunoGen from C4 Therapeutics (CCCC), where she served as CFO, Treasurer, and Principal Accounting Officer, developing and leading the company's financial strategy and operations.

06:27 EDT CAE, Air Europa announce long-term agreement - CAE and Air Europa announced that they are building on their longstanding partnership with a long-term agreement to provide pilot and cabin crew training in Madrid, Spain. As part of this agreement, CAE will deploy a B737NG full-flight simulator, or FFS, at its Madrid training center in October. The latest-generation CAE 7000 XR-Series Level D FFS will provide an immersive pilot training experience and add training capacity to support the growth of Air Europa and Air Europa Express. In addition, CAE Madrid will become Air Europa's cabin crew training base, with a new B787 door trainer bringing new capabilities to the center.

06:03 EDT Li-Cycle, Glencore accelerate plans for European recycling hub - Li-Cycle and Glencore International AG, a wholly-owned subsidiary of Glencore plc, a leading producer, announced plans for a two-phase approach to the Portovesme Hub project in Sardinia, Italy to expedite the production of battery-grade lithium carbonate. Phase 1 is designed to process up to 11,000 tonnes of black mass annually and, subject to receipt of all final regulatory approvals and definitive agreements, is expected to start operations in the first half of 2024, accelerating the recovery of lithium carbonate and strengthening Li-Cycle's first-mover advantage in Europe. The capital efficient Phase 1 project is expected to produce up to 1,500 tonnes of lithium carbonate, as well as up to 3,000 tonnes of contained nickel and up to 500 tonnes of contained cobalt per year. The previously announced Portovesme Hub project plan remains the same. The company expects the Phase 2 facility to have 50,000 to 70,000 tonnes of black mass processing capacity, and to produce up to 16,500 tonnes of lithium carbonate, as well as up to 18,000 tonnes of contained nickel and 2,250 tonnes of contained cobalt per year. Phase 2 is expected to be the final long-term plan and capacity for the facility. The Portovesme Hub is being designed to be able to process all forms of lithium-ion based black mass, including lithium iron phosphate materials.

05:30 EDT Amazon announces Prime Big Deal Days - Prime members can start their shopping early this upcoming season with Amazon's Prime Big Deal Days, beginning on October 10 at 3 a.m. EDT and running through October 11. Amazon will make it easier for Prime members to find deals they're interested in with personalized recommendations based on past purchases, browsing history, and items saved to their Lists.

05:25 EDT Lithia & Driveway to acquire UK motor, fleet management divisions of Pendragon - Lithia & Driveway announced that it intends to enter a strategic partnership with Pinewood Technologies and acquire the UK motor and fleet management divisions of Pendragon, the UK's third largest automotive dealership group. This acquisition will round out Lithia's presence in the UK market and is expected to generate over $4.5B in annual revenues. Lithia and Pendragon have signed agreements to enter a strategic partnership with Pinewood Technologies and for Lithia to acquire Pendragon's UK motor division and vehicle management division. As part of the agreement, the ongoing Pendragon business, comprised of the Pinewood DMS platform, will remain listed on the London Stock Exchange under the name Pinewood Technologies and will become pure play software as a service business with its profitable Pinewood dealer management system. Lithia's UK operations will grow their digital capabilities by adopting the Pinewood technology platform across all locations. Additionally, Lithia and Pinewood Technologies, through a joint venture, will co-develop automotive technology solutions to capitalize on the North American market opportunity. Lastly, Lithia will take a 16.7% ownership in the remaining Pinewood business at completion of the transaction. The acquisition of Pendragon Vehicle Management immediately adds a fleet management services business to Lithia. This business-to-business fleet management model will start the foundation for global growth in this adjacency. PVM's experienced leadership team will continue leading the business with a focus on growth.

05:14 EDT Kite announces Alycante study met primary endpoint - Kite, a Gilead company, announced results from the Phase 2 Alycante study, led and sponsored by the French collaborative group LYSA/LYSARC, for use of its chimeric antigen receptor, or CAR, T-cell therapy Yescarta in patients with relapsed/refractory large B-cell lymphoma after one prior line of therapy who were deemed ineligible for high-dose chemotherapy and autologous stem cell transplantation. The full findings from the study were published in Nature Medicine. The Alycante study, a multicenter, open-label Phase 2 LYSA study, evaluated for the first time the efficacy and safety of Yescarta as a second-line therapy in 62 patients with R/R LBCL who were deemed ineligible for HDCT and ASCT. The study met its primary endpoint, with a complete metabolic response of 71% at 3 months versus 12% expected with standard of care. At six months, 59.7% of patients remained in CMR. CMR is defined as negative findings on a PET study during or following antitumor therapy. Best objective response and complete response rates were 91.9% and 82.3%, respectively. After a median follow-up of 12 months, median progression-free survival from infusion was 11.8 months, and 48.8% of patients evaluated were alive and progression-free at 12 months. Median overall survival was not reached. OS at 12 months was 78.3%. Yescarta showed an acceptable safety profile in this population, who are considered unfit for HDCT/ASCT; 8.1% and 14.5% experienced Grade 3-4 cytokine-release syndrome or Immune Effector Cell Associated Neurotoxicity Syndrome, respectively. In clinical practice, about half of patients with R/R LBCL are considered ineligible for HDCT/ASCT due to factors including advanced age, frailty, and coexisting medical conditions. The Alycante study included patients deemed ineligible for HDCT/ASCT because of age 65 years, high hematopoietic cell transplantation-specific comorbidity index score of 3, and/or prior ASCT.